Mythical Games Announces Launch of New Marketplace and Acquisition of DMarket
25.1.2023 15:00:00 EET | Business Wire | Press release
Mythical Games, the next-generation gaming technology studio, has launched Mythical Marketplace 2.0 following the acquisition of marketplace tech start-up DMarket, as part of its continued commitment to innovation in gaming. The new marketplace is built on Mythical’s new layer 1 EVM blockchain and powered by the Mythos native ecosystem token, MYTH. The acquisition is a significant milestone for Mythical Games, with DMarket’s tech facilitating the most advanced trading platform for digital assets. It makes Mythical the world’s second-largest processor of digital assets on a distributed ledger after the Ethereum mainnet, as of December.
Mythical’s Marketplace 2.0 has fully integrated DMarket’s technology to feature principles of its blended payment gateway, featuring a powerful AML and anti-fraud protection system built on more than a decade of industry experience. Combined with Mythical’s expertise in gaming and digital assets, Marketplace 2.0 provides a frictionless user experience that enables peer-to-peer transactions and empowerment for gamers looking to participate in the play-and-own gaming economies of the future. The Mythical Chain has been live for six weeks, processing over 2 million transactions.
“We founded Mythical Games in 2018 with the idea of ushering in both the next generation of gaming and the next generation of gamers. Half a decade later, we’re continuing to do just that. Mythical’s Marketplace 2.0 was designed to not only enhance our platform but, more importantly, improve the player experience and set the standard for the future of gaming,” said John Linden, co-founder and CEO, Mythical Games. “All too often, developers tout features as ‘seamless’ and ‘integrated’ when discussing gaming or metaverse projects. In reality, these solutions are still very complicated and not made for gamers. But with these monumental steps forward, Mythical will provide users with an experience that delivers on both.”
Marketplace 2.0 will support NFL Rivals and Nitro Nation World Tour assets, with plans to expand to all Mythical titles on the Mythical Chain. Assets on the Mythical Chain will be entirely governed by smart contracts with both ownership and commerce logic enforced on a secure distributed digital ledger.
“The new horizons of the gaming space have always been the main focus for DMarket. We’re excited to become a part of Mythical Games' work to reduce barriers to entry for innovative game developers and thriving new economies,” said Vlad Panchenko, co-founder and CEO of DMarket. “We share a vision of how the industry will evolve and how we all can contribute and bring more fun to the gaming community worldwide.”
DMarket’s office in Kyiv, Ukraine, becomes part of Mythical East, with its headquarters in Lisbon, Portugal. Its co-founders, Vlad Panchenko and Tamara Slanova, will become part of Mythical’s Executive leadership team, with a particular focus on building the best and easiest marketplace technology for the gaming industry.
DMarket has also adopted the Mythical Chain for its existing marketplace, which will continue to operate outside of the Mythical Marketplace. DMarket.com will retain the familiar experience with purchases in USD in the web experience; however, all trades are recorded on the Mythical Chain to provide full transparency to the community.
For more information on Mythical Games’ Marketplace 2.0, visit http://mythical.market.
About Mythical Platform
Mythical Platform can be added to pre-existing game economies or built into the design of a new game from the ground up, and enables management of digital asset trades, payments, users, and inventory management, making it possible for buyers and sellers of digital assets to transact confidently in an environment founded on transparency, security, trust and value. Mythical Marketplace provides seamless integration to game inventory and offers fraud protection, fee optimization, and soon asset bundling and buyer and seller pricing recommendations. Mythical partners will also have access to proprietary intelligence, market design and market intervention tools that enable easy and safe digital asset transactions.
About Mythical Games
Acknowledged by Forbes’ Disruptive Technology Companies to Watch in 2019 and Fast Company’s World Changing Ideas 2021, Mythical is a next-generation games technology company creating a gaming ecosystem by leveraging tradeable digital assets for tools that enable players, creators, artists, brands and game developers to become stakeholders and owners in new creator-focused game economies.
Led by gaming industry veterans, the team specializes in building games around player-owned economies and has helped develop major franchises, including Call of Duty, World of Warcraft, Guitar Hero, DJ Hero, Marvel Strike Force and Skylanders.
About DMarket
DMarket is the biggest marketplace for trading gaming and esports digital assets. Based on the Newzoo report, it is also one of the top three blockchain-based marketplaces worldwide. The company was founded in 2017 by serial entrepreneurs Vlad Panchenko and Tamara Slanova. DMarket's partners and customers include Darewise, GSC Game World, the Na’Vi esports team, Unity, Xsolla, and others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124006123/en/
Contact information
Nate Nesbitt
nate.nesbitt@mythical.games
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom